Table 3 Performance of cfnucleosome biomarker panels with and without CA 19-9
From: Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer
CA 19-9 | 4 NuQ® assays | 5 NuQ® assays | 4 NuQ® assays + CA 19-9 | |||||
|---|---|---|---|---|---|---|---|---|
Clinical question | AUC | Sensitivity (%) | AUC | Sensitivity (%) | AUC | Sensitivity (%) | AUC | Sensitivity (%) |
(90 % specificity) | (90 % specificity) | (90 % specificity) | (90 % specificity) | |||||
Cancer vs. healthy | 0.87 | 80 | 0.91 | 68 | 0.95 | 84 | 0.98 | 92 |
Cancer vs. healthy and benign | 0.84 | 72 | 0.90 | 64 | 0.92 | 72 | 0.94 | 92 |